Yang Tian1,2, Dongmei Wang1,2, Gaoxia Wei1,2, Jiesi Wang1,2, Huixia Zhou1,2, Hang Xu1,2, Qilong Dai1,2, Meihong Xiu3, Dachun Chen3, Li Wang1,2, Xiang Yang Zhang4,5. 1. CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, 16 Lincui Road, Chaoyang District, Beijing, 100101, China. 2. Department of Psychology, University of Chinese Academy of Sciences, Beijing, China. 3. Beijing HuiLongGuan Hospital, Peking University, Beijing, China. 4. CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, 16 Lincui Road, Chaoyang District, Beijing, 100101, China. zhangxy@psych.ac.cn. 5. Department of Psychology, University of Chinese Academy of Sciences, Beijing, China. zhangxy@psych.ac.cn.
Abstract
OBJECTIVE: People with schizophrenia exhibit a high obesity rate. However, little is known about the prevalence of obesity and its relationship with clinical symptoms and metabolic indicators in first-episode drug-naïve (FEDN) schizophrenia. METHODS: Demographic and lipid parameters were gathered from 297 FEDN schizophrenia and 325 healthy controls. The patients' symptomatology was evaluated by the Positive and Negative Syndrome Scale (PANSS). RESULTS: The obesity rate of FEDN patients was 10.77%, similar to that of controls (10.5%). The prevalence of overweight plus obesity of patients was 44.8%, significantly higher than that of controls (36.6%). Compared with non-obese patients, obese patients had higher levels of cholesterol (4.81 ± 0.93 vs 4.22 ± 1.00 mmol/L), triglyceride (0.27 ± 0.21 vs 0.14 ± 0.24 mg/dL), low-density lipoprotein (0.48 ± 0.12 vs 0.40 ± 0.12 mg/dL), greater ratio of triglyceride/high-density lipoprotein (2.01 ± 1.23 vs 1.44 ± 1.26), and higher PANSS positive symptom subscale score (29.81 ± 6.29 vs 27.05 ± 6.15), general psychopathology subscale score (70.75 ± 11.74 vs 66.87 ± 11.37), and total score (149.81 ± 21.08 vs 140.64 ± 21.58), but lower high-density lipoprotein level (1.09 ± 0.21 vs 1.27 ± 0.34 mg/dL) (all p < 0.05). Correlation analysis revealed that body mass index (BMI) was positively correlated with triglyceride, cholesterol, high-density lipoprotein, low-density lipoprotein, triglyceride/high-density lipoprotein ratio, PANSS positive symptoms, general psychopathology, and total scores (all p < 0.05, r = 0.124 ~ 0.335). Multiple regression analysis confirmed that PANSS positive symptoms, total score, and cholesterol level were significantly associated with BMI (all p < 0.05, β: 0.126-0.162). CONCLUSION: There was no significant difference in the prevalence of obesity between FEDN patients and the control group. Moreover, BMI was positively associated with positive symptom severity in FEDN patients.
OBJECTIVE:People with schizophrenia exhibit a high obesity rate. However, little is known about the prevalence of obesity and its relationship with clinical symptoms and metabolic indicators in first-episode drug-naïve (FEDN) schizophrenia. METHODS: Demographic and lipid parameters were gathered from 297 FEDN schizophrenia and 325 healthy controls. The patients' symptomatology was evaluated by the Positive and Negative Syndrome Scale (PANSS). RESULTS: The obesity rate of FEDN patients was 10.77%, similar to that of controls (10.5%). The prevalence of overweight plus obesity of patients was 44.8%, significantly higher than that of controls (36.6%). Compared with non-obesepatients, obesepatients had higher levels of cholesterol (4.81 ± 0.93 vs 4.22 ± 1.00 mmol/L), triglyceride (0.27 ± 0.21 vs 0.14 ± 0.24 mg/dL), low-density lipoprotein (0.48 ± 0.12 vs 0.40 ± 0.12 mg/dL), greater ratio of triglyceride/high-density lipoprotein (2.01 ± 1.23 vs 1.44 ± 1.26), and higher PANSS positive symptom subscale score (29.81 ± 6.29 vs 27.05 ± 6.15), general psychopathology subscale score (70.75 ± 11.74 vs 66.87 ± 11.37), and total score (149.81 ± 21.08 vs 140.64 ± 21.58), but lower high-density lipoprotein level (1.09 ± 0.21 vs 1.27 ± 0.34 mg/dL) (all p < 0.05). Correlation analysis revealed that body mass index (BMI) was positively correlated with triglyceride, cholesterol, high-density lipoprotein, low-density lipoprotein, triglyceride/high-density lipoprotein ratio, PANSS positive symptoms, general psychopathology, and total scores (all p < 0.05, r = 0.124 ~ 0.335). Multiple regression analysis confirmed that PANSS positive symptoms, total score, and cholesterol level were significantly associated with BMI (all p < 0.05, β: 0.126-0.162). CONCLUSION: There was no significant difference in the prevalence of obesity between FEDN patients and the control group. Moreover, BMI was positively associated with positive symptom severity in FEDN patients.
Entities:
Keywords:
Body mass index; Clinical symptom; First-episode drug-naïve with schizophrenia; Obesity
Authors: Roman Balõtšev; Liina Haring; Kati Koido; Vambola Leping; Kärt Kriisa; Mihkel Zilmer; Veiko Vasar; Anneli Piir; Aavo Lang; Eero Vasar Journal: Early Interv Psychiatry Date: 2017-07-18 Impact factor: 2.732
Authors: D C Chen; X D Du; G Z Yin; K B Yang; Y Nie; N Wang; Y L Li; M H Xiu; S C He; F D Yang; R Y Cho; T R Kosten; J C Soares; J P Zhao; X Y Zhang Journal: Psychol Med Date: 2016-09-08 Impact factor: 7.723
Authors: Christoph U Correll; Peter Manu; Vladimir Olshanskiy; Barbara Napolitano; John M Kane; Anil K Malhotra Journal: JAMA Date: 2009-10-28 Impact factor: 56.272
Authors: Mario Alvarez-Jiménez; César González-Blanch; Benedicto Crespo-Facorro; Sarah Hetrick; Jose Manuel Rodríguez-Sánchez; Rocio Pérez-Iglesias; Jose Luis Vázquez-Barquero Journal: CNS Drugs Date: 2008 Impact factor: 5.749
Authors: Mercedes Clemente-Postigo; Maria Isabel Queipo-Ortuño; Diego Fernandez-Garcia; Ricardo Gomez-Huelgas; Francisco J Tinahones; Fernando Cardona Journal: PLoS One Date: 2011-09-22 Impact factor: 3.240